SEC Form 3 · accession 0001323304-26-000004
ADARx Pharmaceuticals, Inc. · ADRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mary Tagliaferri
Director
Period of report
Sep 24, 2026
Accepted (ET)
Sep 24, 2026 · 6:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001802369
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $6.25 | holding | — | — | — | — | Nov 21, 2035 | Common Stock | 178,528 | — | D |
| Stock Option (right to buy)F2 | $8.69 | holding | — | — | — | — | Jul 19, 2036 | Common Stock | 178,528 | — | D |
Explanation of responses
- F1Granted to the Reporting Person on November 22, 2025. 1/4 of the total number of shares vest and become exercisable on November 22, 2026 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- F2Granted to the Reporting Person on July 20, 2026. 1/4 of the total number of shares vest and become exercisable on July 20, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Remarks
Exhibit 24 - Power of Attorney